|
× |
 |
Article: Calendar of events |
€2.42 |
|
€2.42 (incl. VAT) |
|
× |
|
Article: Clinically meaningful survival benefit with atezolizumab + nab-paclitaxel in previously untreated patients with PD-L1+ metastatic triple negative breast cancer |
€2.42 |
|
€2.42 (incl. VAT) |
|
× |
|
Article: Highlights in genitourinary cancers |
€2.42 |
|
€2.42 (incl. VAT) |
|
× |
|
Article: Highlights in gynaecological cancers |
€2.42 |
|
€2.42 (incl. VAT) |
|
|
Top
